Massimo Cristofanilli on Muck Rack

Massimo Cristofanilli

New York
As seen in: Nature, MDPI, U.S. News and World Report, The New England Journal of Medicine, The Lancet, Cancer Discovery, Future Medicine, ONCOLOGY journal, CURE Magazine, OncLive and
Associate Director for Precision Medicine, Director of Breast Medical Oncology, Scientific Director Englander IPM @WeillCornell
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Massimo

Contact Massimo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer

|
By François-Clément Bidard, Carlos H. Barrios Verified, Giampaolo Bianchini, Adam Brufsky, Stephen Chia, Javier Cortés, Massimo Cristofanilli, Giuseppe Curigliano, Shaheenah Dawood, Lorenzo Gerratana, Antonio Giordano, Michail Ignatiadis, Hiroji Iwata, Wolfgang Janni, Elgene Lim, Kevin Kalinsky, Cynthia X. MA, Erica L. Mayer, Arielle Medford, Jason A. Mouabbi, Joyce O’Shaughnessy, Yeon Hee Park, Javier G. Pascual, Pedram Razavi, Sarah L. Sammons, Jose Sandoval, Luisana Sisca, Paolo Tarantino, Seth A. Wander, Gustavo Werutsky, Nicholas Turner
| Nature Verified
Introduction In patients treated with first-line AI plus CDK4/6 inhibitor, SERENA-6 showed the benefit of switching from an aromatase inhibitor to the oral SERD camizestrant upon detection of an emerging ESR1 mutation, before disease progression. While this adaptive oncology approach has shown key benefits for patients, the integration of emerging ctDNA targets into treatment decisions has been questioned.
Open in Who Shared Issue with article?

Circulating cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq) in oncology: from technological advances to clinical applications

|
By Edoardo Francini, Sara Bleve, Giuseppe Nicolò Fanelli, Mara Serena Serafini, Filippo Pederzoli, Alessandra Ferri, Jacopo Venturini, Sílvia Rodrigues, Hubert Pakula, Cristian Lolli, Massimo Cristofanilli, Erika Minonne
| Nature Verified
Abstract Circulating cell-free DNA (cfDNA) methylation profiling enables minimally invasive cancer detection and monitoring. Among available methods, cfMeDIP-seq is a sensitive, scalable, bisulfite-free approach suitable for low-input cfDNA. This review summarizes its principles, comparative technologies, and clinical applications, including early detection, tumor classification, and minimal residual disease monitoring.
Open in Who Shared Issue with article?

First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer | NEJM

|
By Massimo Cristofanilli, Giampaolo Bianchini
| The New England Journal of Medicine Verified
Notes This article was published on June 1, 2025, and updated on July 24, 2025, at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. Supported by AstraZeneca. Dr. Bidard is supported by a grant (ANR-23-IAHU-0006) from the Women’s Cancer Institute of Institut Curie. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
Open in Who Shared Issue with article?
See all 18 licensed articles (42 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified